Norges Bank
VERA icon

Norges Bank’s Vera Therapeutics VERA Stock Holding History

Norges Bank’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-188,422
Closed -$4.44M – 1510
2025
Q2 		$4.44M Buy
188,422
+134,418
+249% +$3.02M ﹤0.01% 1341
2025
Q1 		$1.3M Buy
54,004
+5,411
+11% +$174K ﹤0.01% 1588
2024
Q4 		$2.05M Buy
+48,593
New +$2.15M ﹤0.01% 1686

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's VERA Position: Q3 2025 in Review

Norges Bank sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 188,422 shares — an estimated $4.44M sold.

Norges Bank first reported a position in VERA in Q4 2024 and held it in 3 quarters. The position peaked at $4.44M in Q2 2025. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

  • Norges Bank reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 188,422 Vera Therapeutics shares in Q3 2025, an estimated $4.44M.
  • Norges Bank first reported a position in Vera Therapeutics in Q4 2024 and held it in 3 quarters.
  • Norges Bank's Vera Therapeutics position peaked at $4.44M in Q2 2025.
  • 175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.